Navigation Links
Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
Date:2/17/2009

VE EXPENSES 13,282,421 10,311,750 26,634,396 17,133,166 INCOME FROM OPERATIONS 11,425,697 8,483,150 18,772,853 13,417,584 OTHER (INCOME) EXPENSE: Other (income) expense, net 429,559 (40,185) 1,344,529 (27,507) Other (income) expense - related parties (92,774) (26,944) (236,724) (53,436) Non-operating (income) expense (225,558) (59,606) (150,937) 297 Interest expense, net 1,549,331 339,484 2,902,125 399,484 Loss from Discontinued Operations 1,545,607 112,931 1,590,823 112,931 OTHER EXPENSE, NET 3,206,165 325,680 5,449,816 431,769 INCOME BEFORE PROVISION FOR INCOME TAXES 8,219,532 8,157,470 13,323,037 12,985,815 PROVISION FOR INCOME TAXES 2,820,346 3,004,007 4,790,367 4,597,360 NET INCOME 5,399,186 5,153,463 8,532,670 8,388,455 OTHER COMPREHENSIVE INCOME: Unrealized Holding (loss) gain (384,650) 1,618,203 (1,947,617) 1,618,203 Foreign currency Translation Adjustment 248,823 1,050,485 579,464 1,467,831 COMPREHENSIVE INCOME $5,263,359 $7,822,151 $7,164,517 $11,474,489 BASIC WEIGHTED AVERAGE NUMBER OF SHARES 9,771,883 9,641,742 9,770,615 5,907,192 BASIC EARNINGS PER SHARE $0.55 $0.53 $0.87 $1.42 DILUTED WEIGHTED AVERAGE NUMBER OF SHARES 10,418,317 10,206,553 10,443,463 6,472,003 DILUTED EARNINGS PER SHARE $0.11 $0.02 $0.41 $0.53 GENESIS PHARMACEUTICALS ENTERPRISES, INC. AND SUBSIDIARIE
'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
3. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
4. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. OmegaGenesis Announces Angiogenesis Application Collaboration
7. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
8. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
9. Cardiogenesis Reports Third Quarter 2008 Results
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. Genesis Pharmaceuticals Launches New Corporate Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Vieillard as Sales & Marketing Director. , With more than 25 years ... responsible for reinforcing Tronics’ business development activities worldwide. He brings to the company ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... Sept. 30 From November 19 - 22,2008, ... 40th,International Trade Fair with Congress - World Forum ... the medical industry, MEDICA 2008 will,feature about 4,300 ... special events., Exhibit categories at MEDICA 2008 ...
... study shows quota-based plans most popular among ... device and technology products, EVANSTON, Ill., ... Research (IPR) study, conducted by global sales ... ), finds that an,increasing number of companies ...
... (Nasdaq: VRNM ), a pioneer in the ... announced today,that Janet Roemer, Executive Vice President and ... upcoming William Blair & Company 2008,Small-Cap Growth Stock ... a.m. ET on Tuesday, October 7, 2008 and ...
Cached Biology Technology:MEDICA 2008 Returns in November 2Quota-Based Compensation Plans Outpace Ranking Plans 2Quota-Based Compensation Plans Outpace Ranking Plans 3Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference 2Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference 3
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... DUBLIN , July 07, 2015 ... has announced the addition of the "Biometrics ... and Forecasts 2015-2020" report to their offering. ... a major contributor to this growth and the ... US$5.5 billion in revenue for companies involved in ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... of "tumor stem cells" maintains that a rare, stem cell-like ... cells found in a tumor and that these tumor stem ... revolutionary study appearing in the June 1 print issue of ... the Sidney Kimmel Cancer Center evaluated 1122 cancer patients diagnosed ...
... findings with implications for pandemic influenza, a new study reports ... influenza virus can spread from poultry to humans. The ... of Infectious Diseases, now available online. , Crossing the species ... flu virus with pandemic potential. Previous studies have focused on ...
... in southwest China suffer from potentially-crippling fluoride poisoning because ... researchers. , The findings, from a study carried out ... disease was caused by people burning fluoride-rich coal in ... last year, the Chinese authorities invested 34 million yuan ...
Cached Biology News:Eating, body weight regulated by specific neurons 2Fluoride poisoning in China due to clay, not coal 2
... Myeloblastosis Virus Reverse Transcriptase (AMV RT) catalyzes ... RNA or RNA:DNA hybrids (1). It requires ... than RNA primers) as well as Mg2+ ... RNase H activity. Both nonionic detergents and ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... RNase-Free DNase is a preparation of ... double-stranded DNA to produce 3-hydroxyl oligonucleotides. ... in applications where maintaining the integrity ... is qualified for use with the ...
... Liquid. In 100 mM KCl, 20 ... 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. Human ... protein of 765 amino acids encoded by a ... positive and negative supercoiled DNAs without the requirement ...
Biology Products: